Takehiro Hasegawa
Research Subjects
Research Interests
Takehiro Hasegawa has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Ortiz
Department of Nephrology and Hypertension, IIS-Fundacion Jimenez Diaz UAM , Madrid
2 shared publications - Ayano Fukushima-Nomura
Department of Dermatology Keio University School of Medicine Tokyo Japan
2 shared publications - Beatriz Fernandez-Fernandez
IIS-Fundacion Jimenez Diaz UAM , Madrid
2 shared publications Eiya Tamada
Sysmex Corporation, Kobe, Japan
2 shared publications- Haruhiko Koseki
Laboratory for Developmental Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
2 shared publications - Keisuke Tomii
Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan
2 shared publications
Latest Publications
- Open Access
Longer Asthma Duration Is Associated With Elevated Non‐ T2 Sputum Biomarkers and Reduced T2 Inflammation in Severe Asthma
Background: Longer asthma duration predicts non‐remission in Type‐2 (T2) biologic‐treated severe asthma, but underlying mechanisms remain unclear. We investigated associations between asthma duration and inflammatory biomarkers that may explain differential biologic response. Methods: We analysed cross‐sectional data from adults with severe asthma in U‐BIOPRED. Asthma duration was defined as years from diagnosis to study entry. T2 and non‐T2 biomarkers were measured in blood and sputum. Identical assays were performed in PRISM, a validation cohort of biologic‐initiators. Multivariable regression models adjusted for age, sex, ethnicity, BMI, smoking and oral corticosteroid dose. Associations between duration‐related biomarkers and 12‐month biologic remission were explored in PRISM. Results: In U‐BIOPRED ( n = 411), median asthma duration was 23 years (IQR 12–38). Longer duration was associated with higher non‐T2 biomarkers including sputum CXCL9 ( β = 0.024, 95% CI 0.011–0.038), sputum IL‐6 ( β = 0.024, 95% CI 0.011–0.037) and sputum neutrophils ( β = 0.009, 95% CI 0.001–0.017), but lower T2 biomarkers including plasma periostin ( β = −0.006, 95% CI −0.009 to −0.003), eosinophils (blood: β = −0.002, 95% CI −0.003 to −0.001; sputum: β = −0.023, 95% CI −0.035 to −0.011), sputum EDN ( β = −0.032, 95% CI −0.049 to −0.014) and FeNO ( β = −0.006, 95% CI −0.010 to −0.001). PRISM ( n = 474) confirmed these associations. Higher sputum CXCL9 was associated with reduced remission in anti‐IL‐4Rα‐treated patients with asthma duration ≥ 20 years ( β = −1.73, 95% CI −3.180 to −0.276). Conclusion: Longer asthma duration was associated with elevated airway non‐T2 inflammation and reduced systemic and airway T2 inflammation. This highlights the importance of airway biomarker sampling and suggests combined T2 and non‐T2 therapeutic strategies may be needed to achieve remission in long‐standing asthma. Trial Registration: ClinicalTrials.gov identifier: NCT05164939
Open AccessLonger Asthma Duration Is Associated With Elevated Non‐ T2 Sputum Biomarkers and Reduced T2 Inflammation in Severe Asthma
Background: Longer asthma duration predicts non‐remission in Type‐2 (T2) biologic‐treated severe asthma, but underlying mechanisms remain unclear. We investigated associations between asthma duration and inflammatory biomarkers that may explain differential biologic response. Methods: We analysed cross‐sectional data from adults with severe asthma in U‐BIOPRED. Asthma duration was defined as years from diagnosis to study entry. T2 and non‐T2 biomarkers were measured in blood and sputum. Identical assays were performed in PRISM, a validation cohort of biologic‐initiators. Multivariable regression models adjusted for age, sex, ethnicity, BMI, smoking and oral corticosteroid dose. Associations between duration‐related biomarkers and 12‐month biologic remission were explored in PRISM. Results: In U‐BIOPRED ( n = 411), median asthma duration was 23 years (IQR 12–38). Longer duration was associated with higher non‐T2 biomarkers including sputum CXCL9 ( β = 0.024, 95% CI 0.011–0.038), sputum IL‐6 ( β = 0.024, 95% CI 0.011–0.037) and sputum neutrophils ( β = 0.009, 95% CI 0.001–0.017), but lower T2 biomarkers including plasma periostin ( β = −0.006, 95% CI −0.009 to −0.003), eosinophils (blood: β = −0.002, 95% CI −0.003 to −0.001; sputum: β = −0.023, 95% CI −0.035 to −0.011), sputum EDN ( β = −0.032, 95% CI −0.049 to −0.014) and FeNO ( β = −0.006, 95% CI −0.010 to −0.001). PRISM ( n = 474) confirmed these associations. Higher sputum CXCL9 was associated with reduced remission in anti‐IL‐4Rα‐treated patients with asthma duration ≥ 20 years ( β = −1.73, 95% CI −3.180 to −0.276). Conclusion: Longer asthma duration was associated with elevated airway non‐T2 inflammation and reduced systemic and airway T2 inflammation. This highlights the importance of airway biomarker sampling and suggests combined T2 and non‐T2 therapeutic strategies may be needed to achieve remission in long‐standing asthma. Trial Registration: ClinicalTrials.gov identifier: NCT05164939
- Open Access
Interleukin‐22 and Interleukin‐18 as Potential Blood Biomarkers in Dupilumab‐Treated Atopic Dermatitis
- Open Access
- 9 December 2025
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (4)
Systemic inflammatory profiles are associated with long-term kidney failure and patient mortality in chronic kidney disease
Background: Chronic kidney disease (CKD) is frequently associated with systemic inflammation. However, the relationship between inflammatory cytokines and CKD progression remains incompletely understood. Methods: The PROGRESER study (Factores de PROGRESion en Enfermedad Renal) was a multicentre, prospective observational cohort that included patients with CKD stage G3. A total of 17 plasma and 10 urinary inflammatory cytokines were measured in 165 participants, at baseline, 18 months and 36 months, using a fully automated HISCL immune analyser. Unsupervised cluster analysis identified six distinct patient clusters. Associations between cytokine levels and kidney outcomes [estimated glomerular filtration rate (eGFR), urinary albumin-to-creatinine ratio (uACR), KDIGO risk scores, kidney replacement therapy (KRT)], cardiovascular outcomes (cardiovascular hospitalization) and death was assessed during a follow-up of up to 10 years. The primary outcome was a combination of KRT or death. Results: Plasma levels of 15 cytokines and 6 urinary cytokines differed between patients with CKD and 30 healthy controls. Of these, plasma interleukin (IL)-8 levels were inversely associated with uACR slopes, while IL-22, tumour necrosis factor (TNF)-α and Growth Differentiation Factor 15 (GDF-15) levels showed positive correlations with uACR progression. Additionally, plasma TNF-α and GDF-15 were associated with KRT and/or death with 10 years. Cluster analysis of plasma IL-8, IL-22, TNF-α and GDF-15 identified six distinct patient clusters. Clusters 3 (elevated levels of IL-22, TNF-α, GDF-15), 4 (elevated levels of all four cytokines) and the uncommon Cluster 5 (high GDF-15 only) were associated with worse kidney, cardiovascular and survival outcomes, while Cluster 6 (low cytokine levels) represented patients with slower disease progression and the best long-term outcomes. Over time, patients frequently transitioned to more severe clusters. Conclusion: In CKD G3 patients, systemic inflammation can be stratified using cytokine profiles. Specific cytokine clusters are linked to faster progression of CKD and cardiovascular disease, and to worse long-term outcomes including kidney failure and mortality.
- 9 December 2025
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (4)
Open AccessSystemic inflammatory profiles are associated with long-term kidney failure and patient mortality in chronic kidney disease
Background: Chronic kidney disease (CKD) is frequently associated with systemic inflammation. However, the relationship between inflammatory cytokines and CKD progression remains incompletely understood. Methods: The PROGRESER study (Factores de PROGRESion en Enfermedad Renal) was a multicentre, prospective observational cohort that included patients with CKD stage G3. A total of 17 plasma and 10 urinary inflammatory cytokines were measured in 165 participants, at baseline, 18 months and 36 months, using a fully automated HISCL immune analyser. Unsupervised cluster analysis identified six distinct patient clusters. Associations between cytokine levels and kidney outcomes [estimated glomerular filtration rate (eGFR), urinary albumin-to-creatinine ratio (uACR), KDIGO risk scores, kidney replacement therapy (KRT)], cardiovascular outcomes (cardiovascular hospitalization) and death was assessed during a follow-up of up to 10 years. The primary outcome was a combination of KRT or death. Results: Plasma levels of 15 cytokines and 6 urinary cytokines differed between patients with CKD and 30 healthy controls. Of these, plasma interleukin (IL)-8 levels were inversely associated with uACR slopes, while IL-22, tumour necrosis factor (TNF)-α and Growth Differentiation Factor 15 (GDF-15) levels showed positive correlations with uACR progression. Additionally, plasma TNF-α and GDF-15 were associated with KRT and/or death with 10 years. Cluster analysis of plasma IL-8, IL-22, TNF-α and GDF-15 identified six distinct patient clusters. Clusters 3 (elevated levels of IL-22, TNF-α, GDF-15), 4 (elevated levels of all four cytokines) and the uncommon Cluster 5 (high GDF-15 only) were associated with worse kidney, cardiovascular and survival outcomes, while Cluster 6 (low cytokine levels) represented patients with slower disease progression and the best long-term outcomes. Over time, patients frequently transitioned to more severe clusters. Conclusion: In CKD G3 patients, systemic inflammation can be stratified using cytokine profiles. Specific cytokine clusters are linked to faster progression of CKD and cardiovascular disease, and to worse long-term outcomes including kidney failure and mortality.
- Top Cited PapersOpen Access
- 2 June 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-22
An unbiased tissue transcriptome analysis identifies potential markers for skin phenotypes and therapeutic responses in atopic dermatitis
Atopic dermatitis (AD) is a skin disease exhibiting clinical and molecular heterogeneity, thereby jeopardizing the development of personalized treatments. Here we pursue a cross-sectional and longitudinal cohort analysis of 951 whole-skin samples, employing an unsupervised decomposition analysis to link gene expression profiles to disease severity, six distinct skin phenotypes, and blood cytokines representative of given endotypes. Specifically, type 2 and type 17 responses are associated with major skin phenotypes such as erythema and induration, while type 1 response is upregulated in lichen amyloidosis of AD patients. Longitudinal analysis of patients treated with dupilumab finds sustained gene signatures related to type 17 response in lesional skin and upregulated transcription factors in non-lesional skin of patients with poor treatment outcomes. Lastly, several extracellular matrix organization-associated genes are correlated with clinical severity and treatment response to dupilumab. Our findings thus provide potential skin and blood biomarkers for assessing endotypes and therapeutic responses in AD to pave the way for personalized medicine.
- 2 June 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-22
Top Cited PapersOpen AccessAn unbiased tissue transcriptome analysis identifies potential markers for skin phenotypes and therapeutic responses in atopic dermatitis
Atopic dermatitis (AD) is a skin disease exhibiting clinical and molecular heterogeneity, thereby jeopardizing the development of personalized treatments. Here we pursue a cross-sectional and longitudinal cohort analysis of 951 whole-skin samples, employing an unsupervised decomposition analysis to link gene expression profiles to disease severity, six distinct skin phenotypes, and blood cytokines representative of given endotypes. Specifically, type 2 and type 17 responses are associated with major skin phenotypes such as erythema and induration, while type 1 response is upregulated in lichen amyloidosis of AD patients. Longitudinal analysis of patients treated with dupilumab finds sustained gene signatures related to type 17 response in lesional skin and upregulated transcription factors in non-lesional skin of patients with poor treatment outcomes. Lastly, several extracellular matrix organization-associated genes are correlated with clinical severity and treatment response to dupilumab. Our findings thus provide potential skin and blood biomarkers for assessing endotypes and therapeutic responses in AD to pave the way for personalized medicine.
- Open Access
- 1 August 2024
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 17 (8) , sfae239
Prognostic and therapeutic monitoring value of plasma and urinary cytokine profile in primary membranous nephropathy: the STARMEN trial cohort
Background: Primary membranous nephropathy (PMN) is usually caused by anti-phospholipase A2 receptor (PLA2R) autoantibodies. There are different therapeutic options according to baseline risk. Novel biomarkers are needed to optimize risk stratification and predict and monitor the response to therapy, as proteinuria responses may be delayed. We hypothesized that plasma or urinary cytokines may provide insights into the course and response to therapy in PMN. Methods: Overall, 192 data points from 34 participants in the STARMEN trial (NCT01955187), randomized to tacrolimus–rituximab (TAC-RTX) or corticosteroids–cyclophosphamide (GC-CYC), were analysed for plasma and urine cytokines using a highly sensitive chemiluminescence immunoassay providing a high-throughput multiplex analysis. Results: Baseline (pretreatment) urinary C-X-C motif chemokine ligand 13 (CXCL13) predicted the therapeutic response to TAC-RTX. Cytokine levels evolved over the course of therapy. The levels of nine plasma and six urinary cytokines correlated with analytical parameters of kidney damage and disease activity, such as proteinuria, estimated glomerular filtration rate and circulating anti-PLA2R levels. The correlation with these parameters was most consistent for plasma and urinary growth differentiation factor 15 (GDF15), plasma tumour necrosis factor α and urinary TNF-like weak inducer of apoptosis. Decreasing plasma GDF15 levels were associated with response to GC-CYC. Four clusters of cytokines were associated with different stages of response to therapy in the full cohort, with the less inflammatory cluster associated with remission. Conclusion: PMN displayed characteristic plasma and urine cytokine patterns that evolved over time as patients responded to therapy. Baseline urinary CXCL13 concentration could be a prognostic marker of response to TAC-RTX.
- 1 August 2024
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 17 (8) , sfae239
Open AccessPrognostic and therapeutic monitoring value of plasma and urinary cytokine profile in primary membranous nephropathy: the STARMEN trial cohort
Background: Primary membranous nephropathy (PMN) is usually caused by anti-phospholipase A2 receptor (PLA2R) autoantibodies. There are different therapeutic options according to baseline risk. Novel biomarkers are needed to optimize risk stratification and predict and monitor the response to therapy, as proteinuria responses may be delayed. We hypothesized that plasma or urinary cytokines may provide insights into the course and response to therapy in PMN. Methods: Overall, 192 data points from 34 participants in the STARMEN trial (NCT01955187), randomized to tacrolimus–rituximab (TAC-RTX) or corticosteroids–cyclophosphamide (GC-CYC), were analysed for plasma and urine cytokines using a highly sensitive chemiluminescence immunoassay providing a high-throughput multiplex analysis. Results: Baseline (pretreatment) urinary C-X-C motif chemokine ligand 13 (CXCL13) predicted the therapeutic response to TAC-RTX. Cytokine levels evolved over the course of therapy. The levels of nine plasma and six urinary cytokines correlated with analytical parameters of kidney damage and disease activity, such as proteinuria, estimated glomerular filtration rate and circulating anti-PLA2R levels. The correlation with these parameters was most consistent for plasma and urinary growth differentiation factor 15 (GDF15), plasma tumour necrosis factor α and urinary TNF-like weak inducer of apoptosis. Decreasing plasma GDF15 levels were associated with response to GC-CYC. Four clusters of cytokines were associated with different stages of response to therapy in the full cohort, with the less inflammatory cluster associated with remission. Conclusion: PMN displayed characteristic plasma and urine cytokine patterns that evolved over time as patients responded to therapy. Baseline urinary CXCL13 concentration could be a prognostic marker of response to TAC-RTX.
- 5 September 2021
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 58 (suppl 65) , OA3972
Type 1 inflammatory endotype relates to low compliance, lung fibrosis, and severe complications in COVID-19
Coronavirus disease 2019 (COVID-19) is an acute respiratory disease; approximately 5% of patients developing severe COVID-19. It is known that cytokine release is associated with disease severity, but the relationship between the clinical phenotypes and inflammatory endotypes is not well understood. Therefore, we investigated the association between inflammatory biomarker-based endotypes and severe COVID-19 phenotypes. Interleukin (IL) -6, C-reactive protein (CRP), C–X–C motif chemokine (CXCL) 9, IL-18, C–C motif chemokine (CCL) 3, CCL17, IL-10, and related biomarkers were investigated in 57 COVID-19 patients, and their association with clinical characteristics was examined using a cluster analysis. Significantly higher blood levels of the eight inflammatory markers were noted in patients who developed acute respiratory distress syndrome (ARDS) than in those who did not develop ARDS (non-ARDS). Using a cluster analysis, the patient groups were classified into four clusters, of which two had patients with high IL-6 and CRP levels. In the cluster with high levels of Type 1 (T1) inflammatory markers such as CXCL9 and IL-18, 85% of the patients had ARDS, 65% of the patients developed acute kidney injury (AKI), and 78% of the patients developed pulmonary fibrosis. Furthermore, the levels of T1 inflammatory markers was already higher before ARDS development, than non-ARDS. In the cluster with high levels of T1 inflammatory markers, the patients frequently suffered from tissue damage, manifested as ARDS and AKI. Our findings identified distinct T1 inflammatory endotypes of COVID-19 and suggest the importance of monitoring T1 biomarkers for proactive treatment the severe complications.
- 5 September 2021
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 58 (suppl 65) , OA3972
Type 1 inflammatory endotype relates to low compliance, lung fibrosis, and severe complications in COVID-19
Coronavirus disease 2019 (COVID-19) is an acute respiratory disease; approximately 5% of patients developing severe COVID-19. It is known that cytokine release is associated with disease severity, but the relationship between the clinical phenotypes and inflammatory endotypes is not well understood. Therefore, we investigated the association between inflammatory biomarker-based endotypes and severe COVID-19 phenotypes. Interleukin (IL) -6, C-reactive protein (CRP), C–X–C motif chemokine (CXCL) 9, IL-18, C–C motif chemokine (CCL) 3, CCL17, IL-10, and related biomarkers were investigated in 57 COVID-19 patients, and their association with clinical characteristics was examined using a cluster analysis. Significantly higher blood levels of the eight inflammatory markers were noted in patients who developed acute respiratory distress syndrome (ARDS) than in those who did not develop ARDS (non-ARDS). Using a cluster analysis, the patient groups were classified into four clusters, of which two had patients with high IL-6 and CRP levels. In the cluster with high levels of Type 1 (T1) inflammatory markers such as CXCL9 and IL-18, 85% of the patients had ARDS, 65% of the patients developed acute kidney injury (AKI), and 78% of the patients developed pulmonary fibrosis. Furthermore, the levels of T1 inflammatory markers was already higher before ARDS development, than non-ARDS. In the cluster with high levels of T1 inflammatory markers, the patients frequently suffered from tissue damage, manifested as ARDS and AKI. Our findings identified distinct T1 inflammatory endotypes of COVID-19 and suggest the importance of monitoring T1 biomarkers for proactive treatment the severe complications.
- Open Access
- 2 November 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (11) , e0241719
CXCL9, CXCL10, and CXCL11; biomarkers of pulmonary inflammation associated with autoimmunity in patients with collagen vascular diseases–associated interstitial lung disease and interstitial pneumonia with autoimmune features
Interstitial lung disease (ILD) is a heterogeneous group of diseases characterized by varying degrees of lung inflammation and/or fibrosis. We investigated biomarkers to infer whether patients with collagen vascular diseases associated ILD (CVD–ILD) and interstitial pneumonia with autoimmune features (IPAF) benefit from immunosuppressive therapy. We retrospectively investigated patients with CVD–ILD, IPAF, and idiopathic pulmonary fibrosis (IPF) between June 2013 and May 2017 at our department. First, we assessed differences in serum and bronchoalveolar lavage fluid (BALF) levels of cytokines between groups. Second, we assessed the associations of patient’s clinical variables with serum and BALF levels of those cytokines that were different between groups. Finally, we assessed the associations of diagnosis and response to immunosuppressive therapy with serum levels of those cytokines that were different between groups. We included 102 patients (51 with IPF, 35 with IPAF, and 16 with CVD–ILD). Serum and BALF levels of CXCL9, CXCL10, and CXCL11 were significantly elevated in patients with IPAF or CVD–ILD compared with those in patients with IPF. BALF levels of CXCL9 and CXCL10 were correlated with the percentages of lymphocytes and macrophages in BALF. Serum levels of CXCL9 and CXCL10 were correlated with BALF levels. Serum levels of CXCL9, CXCL10, and CXCL11 were correlated C-reactive protein, percent predicted forced vital capacity, alveolar-arterial oxygen difference, and the percentages of lymphocytes and macrophages in BALF. Serum levels of CXCL9, CXCL10, and CXCL11 showed moderate accuracy to distinguish patients with CVD–ILD from those with IPAF and IPF. Pre-treatment serum levels of CXCL9 and CXCL11 showed strong positive correlations with the annual forced vital capacity changes in patients with IPAF and CVD–ILD treated with immunosuppressive drugs. Serum CXCL9, CXCL10, and CXCL11 are potential biomarkers for autoimmune inflammation and predictors of the immunosuppressive therapy responses in ILD with background autoimmunity.
- 2 November 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (11) , e0241719
Open AccessCXCL9, CXCL10, and CXCL11; biomarkers of pulmonary inflammation associated with autoimmunity in patients with collagen vascular diseases–associated interstitial lung disease and interstitial pneumonia with autoimmune features
Interstitial lung disease (ILD) is a heterogeneous group of diseases characterized by varying degrees of lung inflammation and/or fibrosis. We investigated biomarkers to infer whether patients with collagen vascular diseases associated ILD (CVD–ILD) and interstitial pneumonia with autoimmune features (IPAF) benefit from immunosuppressive therapy. We retrospectively investigated patients with CVD–ILD, IPAF, and idiopathic pulmonary fibrosis (IPF) between June 2013 and May 2017 at our department. First, we assessed differences in serum and bronchoalveolar lavage fluid (BALF) levels of cytokines between groups. Second, we assessed the associations of patient’s clinical variables with serum and BALF levels of those cytokines that were different between groups. Finally, we assessed the associations of diagnosis and response to immunosuppressive therapy with serum levels of those cytokines that were different between groups. We included 102 patients (51 with IPF, 35 with IPAF, and 16 with CVD–ILD). Serum and BALF levels of CXCL9, CXCL10, and CXCL11 were significantly elevated in patients with IPAF or CVD–ILD compared with those in patients with IPF. BALF levels of CXCL9 and CXCL10 were correlated with the percentages of lymphocytes and macrophages in BALF. Serum levels of CXCL9 and CXCL10 were correlated with BALF levels. Serum levels of CXCL9, CXCL10, and CXCL11 were correlated C-reactive protein, percent predicted forced vital capacity, alveolar-arterial oxygen difference, and the percentages of lymphocytes and macrophages in BALF. Serum levels of CXCL9, CXCL10, and CXCL11 showed moderate accuracy to distinguish patients with CVD–ILD from those with IPAF and IPF. Pre-treatment serum levels of CXCL9 and CXCL11 showed strong positive correlations with the annual forced vital capacity changes in patients with IPAF and CVD–ILD treated with immunosuppressive drugs. Serum CXCL9, CXCL10, and CXCL11 are potential biomarkers for autoimmune inflammation and predictors of the immunosuppressive therapy responses in ILD with background autoimmunity.
- Open Access
- 1 January 2020
- Published by Elsevier in SSRN Electronic Journal
Role of T1 Inflammatory Endotype in the Pathophysiology of Severe COVID-19
Background: Coronavirus disease (COVID-19) is a severe acute respiratory disease with approximately 5% of infected persons developing a serious disease. It is known that cytokine release is involved in its mechanism of aggravation, but the understanding of its inflammatory pathophysiology is not sufficiently advanced. Of specific importance to the development of therapeutic strategies is the understanding of its therapeutic endotype.Methods: Peripheral blood cytokines that were identified as being associated with COVID-19 in previous studies and eight inflammatory markers (IL-6, CRP, CXCL9, IL-18, CCL3, CCL17, IL-10, and VEGF) were measured in 57 COVID-19-infected individuals and their association with the patients’ condition was examined using a cluster analysis.Findings: The 8 inflammatory markers had significantly higher blood levels in patients who developed ARDS (ARDS) compared to those who did not develop ARDS during the observation period (non-ARDS). In the cluster analysis, the patient groups were classified into four clusters, of which two of the clusters had patients with high levels of IL-6 and CRP. In these clusters with high levels of IL-6 and CRP, in the clusters with high T1-inflammatory markers such as CXCL9 and IL-18, 85% of the patients had ARDS or pre-ARDS, and 65% of the patients developed AKI.Interpretation: In addition to IL-6 and CRP, which are reported as severity markers, clusters with high T1 inflammatory markers, the patients with high tissue damage have high ARDS and AKI frequency. The existence of different inflammatory endotypes was observed in the patient population with high IL-6 and CRP levels. This difference in inflammatory endotypes provides information essential for the development of therapeutic strategies for anti-inflammatory therapy. Funding: This research was funded by Sysmex Corporation.Declaration of Interests: TH, KS, KY, SY, NI, ET, and NK are employee of Sysmex corporation. TH, KS, and AN patent pending (patent for the biomarker). All other authors declare no competing interests. Ethics Approval Statement: The study complied with the requirements of the Declaration of Helsinki and was approved by the Medical Research Ethics Committee of Kobe City Medical Centre General Hospital and the Sysmex Cooperation. Informed consent was obtained from all of the patients using the following method: In compliance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects, the study information was published on the website and patients at the opportunity to withdraw their consent at any stage of the study. Therefore, the requirement for written informed consent from the enrolled patients was waived by the ethics committee.
- 1 January 2020
- Published by Elsevier in SSRN Electronic Journal
Open AccessRole of T1 Inflammatory Endotype in the Pathophysiology of Severe COVID-19
Background: Coronavirus disease (COVID-19) is a severe acute respiratory disease with approximately 5% of infected persons developing a serious disease. It is known that cytokine release is involved in its mechanism of aggravation, but the understanding of its inflammatory pathophysiology is not sufficiently advanced. Of specific importance to the development of therapeutic strategies is the understanding of its therapeutic endotype.Methods: Peripheral blood cytokines that were identified as being associated with COVID-19 in previous studies and eight inflammatory markers (IL-6, CRP, CXCL9, IL-18, CCL3, CCL17, IL-10, and VEGF) were measured in 57 COVID-19-infected individuals and their association with the patients’ condition was examined using a cluster analysis.Findings: The 8 inflammatory markers had significantly higher blood levels in patients who developed ARDS (ARDS) compared to those who did not develop ARDS during the observation period (non-ARDS). In the cluster analysis, the patient groups were classified into four clusters, of which two of the clusters had patients with high levels of IL-6 and CRP. In these clusters with high levels of IL-6 and CRP, in the clusters with high T1-inflammatory markers such as CXCL9 and IL-18, 85% of the patients had ARDS or pre-ARDS, and 65% of the patients developed AKI.Interpretation: In addition to IL-6 and CRP, which are reported as severity markers, clusters with high T1 inflammatory markers, the patients with high tissue damage have high ARDS and AKI frequency. The existence of different inflammatory endotypes was observed in the patient population with high IL-6 and CRP levels. This difference in inflammatory endotypes provides information essential for the development of therapeutic strategies for anti-inflammatory therapy. Funding: This research was funded by Sysmex Corporation.Declaration of Interests: TH, KS, KY, SY, NI, ET, and NK are employee of Sysmex corporation. TH, KS, and AN patent pending (patent for the biomarker). All other authors declare no competing interests. Ethics Approval Statement: The study complied with the requirements of the Declaration of Helsinki and was approved by the Medical Research Ethics Committee of Kobe City Medical Centre General Hospital and the Sysmex Cooperation. Informed consent was obtained from all of the patients using the following method: In compliance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects, the study information was published on the website and patients at the opportunity to withdraw their consent at any stage of the study. Therefore, the requirement for written informed consent from the enrolled patients was waived by the ethics committee.
- Open Access
- 1 August 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (8) , e0220462
Serum CXCL9 and CCL17 as biomarkers of declining pulmonary function in chronic bird-related hypersensitivity pneumonitis
The clinical course of chronic hypersensitivity pneumonitis (HP) with fibrosis is similar to that of idiopathic pulmonary fibrosis (IPF). Current research is expected to identify biomarkers effective in predicting the deterioration of lung function in a clinical setting. Our group analyzed the relationships between the following parameters in chronic bird-related HP: patient characteristics, serum markers, lung function, HRCT findings, BALF profiles, and the worsening of lung function. We also analyzed serum levels of CXCL9, CCL17, and Krebs von den Lungen 6 (KL-6) as serum markers. Patients showing declines in vital capacity (VC) of over 5% at 6 months after first admission were categorized as the “decline group”; the others were categorized as the “stable group.” The serum level of CCL17 and the percentage of BALF macrophages were significantly higher in the decline group compared to the stable group. Serum levels of CXCL9 and CCL17 were significant variables in a multivariate logistic regression analysis of factors associated with VC decline. Patients with a chemokine profile combining lower serum CXCL9 and higher serum CCL17 exhibited significantly larger VC decline in a cluster analysis. Higher serum CCL17 and lower serum CXCL9 were important predictors of worsening lung function in patients with chronic bird-related HP.
- 1 August 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (8) , e0220462
Open AccessSerum CXCL9 and CCL17 as biomarkers of declining pulmonary function in chronic bird-related hypersensitivity pneumonitis
The clinical course of chronic hypersensitivity pneumonitis (HP) with fibrosis is similar to that of idiopathic pulmonary fibrosis (IPF). Current research is expected to identify biomarkers effective in predicting the deterioration of lung function in a clinical setting. Our group analyzed the relationships between the following parameters in chronic bird-related HP: patient characteristics, serum markers, lung function, HRCT findings, BALF profiles, and the worsening of lung function. We also analyzed serum levels of CXCL9, CCL17, and Krebs von den Lungen 6 (KL-6) as serum markers. Patients showing declines in vital capacity (VC) of over 5% at 6 months after first admission were categorized as the “decline group”; the others were categorized as the “stable group.” The serum level of CCL17 and the percentage of BALF macrophages were significantly higher in the decline group compared to the stable group. Serum levels of CXCL9 and CCL17 were significant variables in a multivariate logistic regression analysis of factors associated with VC decline. Patients with a chemokine profile combining lower serum CXCL9 and higher serum CCL17 exhibited significantly larger VC decline in a cluster analysis. Higher serum CCL17 and lower serum CXCL9 were important predictors of worsening lung function in patients with chronic bird-related HP.
- Open Access
Serum CXCL9 as a potential marker of Type 1 inflammation in the context of eosinophilic asthma